When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund ...

U.S. Consumer Prices Up 0.2%, Core Inflation Exceeds ExpectationsWed, 11 Sep 2024 13:28:21 GMT Fed’s Dilemma: Will Today’s CPI Data Tip the Inflation-Jobs Balance?Wed, 11 Sep 2024 11:42:20 GMT ...

Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages for another claim in which Zurn ruled against it, ...

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai Pharma, Roche's Japanese subsidiary.

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

An AstraZeneca subsidiary owes $130 million to ... Morgan Zurn decided in an opinion that followed a seven-day trial. Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages ...

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

AstraZeneca has built its leading presence ... Also, the recent acquisition of Alexion looks like a solid strategic move done at a reasonable price. The Alexion addition brings in a rare drug ...